Maravai LifeSciences (MRVI)

• Market cap: $728M
• 1 day: -4.47%
• 5 days: -8.39%
• 1 month: -3.02%
• 3 months: -38.19%
• 6 months: -27.44%
• Year to date: -23.89%
• 1 year: -22.74%
• 5 years: -82.81%
• 10 years: -82.81%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Employees: 580

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

822% more call options, than puts

Call options by funds: $2.18M | Put options by funds: $236K

31% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 36

12% more capital invested

Capital invested by funds: $1.07B [Q2] → $1.2B (+$130M) [Q3]

5% more funds holding

Funds holding: 205 [Q2] → 216 (+11) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

6% less repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 68

10.54% less ownership

Funds ownership: 112.27% [Q2] → 101.72% (-10.54%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4.25 17% downside
• Avg. target: $8.75 71% upside
• High target: $13 153% upside

3 analyst ratings

• positive: 2 67%
• neutral: 0 0%
• negative: 1 33%

Goldman Sachs Matthew Sykes 60% 1-year accuracy 27 / 45 met price target	17% downside $4.25	Sell Downgraded	5 Dec 2024
RBC Capital Conor McNamara 21% 1-year accuracy 8 / 39 met price target	153% upside $13	Outperform Maintained	8 Nov 2024
Baird Catherine Schulte 19% 1-year accuracy 4 / 21 met price target	75% upside $9	Outperform Maintained	8 Nov 2024